Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
4.920
-0.080 (-1.60%)
At close: Nov 20, 2026, 4:00 PM EST
4.810
-0.110 (-2.24%)
After-hours: Nov 20, 2026, 5:11 PM EST
Nutriband Revenue
Nutriband had revenue of $437.51K in the quarter ending July 31, 2026, a decrease of -29.71%. This brings the company's total for the last twelve months to $1.62M, down -37.25% year-over-year. In the fiscal year ending January 31, 2026, Nutriband had annual revenue of $2.04M, down -4.81%. That makes Nutriband the 42,806th largest company in the world by revenue and 5,878th in the United States.
Revenue (ttm)
$1.62M
Revenue Growth
-37.25%
P/S Ratio
36.97
Revenue / Employee
$124,437
Employees
13
Market Cap
59.81M
Revenue by Geography
- United States 2.03M 99.6%
- Outside of the United States 7.63K 0.4%
Fiscal year ended Jan 31, 2026 See the full Nutriband breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jan 31, 2026 | 2.04M | -102.89K | -4.81% |
| Jan 31, 2025 | 2.14M | 54.22K | 2.60% |
| Jan 31, 2024 | 2.09M | 5.71K | 0.27% |
| Jan 31, 2023 | 2.08M | 657.46K | 46.23% |
| Jan 31, 2022 | 1.42M | 478.45K | 50.70% |
| Jan 31, 2021 | 943.70K | 573.06K | 154.61% |
| Jan 31, 2020 | 370.65K | 125.36K | 51.11% |
| Jan 31, 2019 | 245.29K | - | - |
| Jan 31, 2018 | - | - | - |
| Jan 31, 2017 | - | - | - |
| Jan 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 60.66M |
| Coherus Oncology | 53.64M |
| NeurAxis | 6.53M |
| Kazia Therapeutics | 1.32M |
| iBio, Inc. | 1.08M |
| MediciNova | 935.72K |
NTRB News
- 5 days ago - Nutriband gets notice of allowance for fentanyl transdermal system from USPTO - TheFly
- 5 days ago - Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System - GlobeNewsWire
- 5 weeks ago - Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274 - GlobeNewsWire
- 6 weeks ago - Nutriband files non-provisional utility Aversa patent application with USPTO - TheFly
- 6 weeks ago - Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology - GlobeNewsWire
- 7 weeks ago - Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders - GlobeNewsWire
- 7 weeks ago - Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis - GlobeNewsWire
- 1 month ago - Nutriband appoints O’Neill to Advisory Board - TheFly